[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"45785a07-9d38-4987-a49f-4d7f22463b54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188664","created_at":"2022-01-12T14:53:34.539Z","updated_at":"2025-02-25T14:08:34.404Z","phase":"Phase 1/2","brief_title":"Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05188664","lead_sponsor":"LaNova Australia Pty Limited","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 11/14/2023","primary_completion_date":" 11/14/2023","study_txt":" Completion: 11/14/2023","study_completion_date":" 11/14/2023","last_update_posted":"2025-02-17"},{"id":"b38928cb-8505-433c-80c6-0b0f9c9ff90b","acronym":"SHR-A1904-I-104","url":"https://clinicaltrials.gov/study/NCT05277168","created_at":"2023-01-18T16:59:24.432Z","updated_at":"2025-02-25T14:16:45.234Z","phase":"Phase 1/2","brief_title":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","source_id_and_acronym":"NCT05277168 - SHR-A1904-I-104","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e garetatug rezetecan (SHR-A1904)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 03/03/2026","primary_completion_date":" 03/03/2026","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2025-02-17"},{"id":"e5e3ad81-9df9-4560-a791-5e9b3953d9ad","acronym":"KYM901","url":"https://clinicaltrials.gov/study/NCT04805307","created_at":"2021-03-18T11:52:24.597Z","updated_at":"2025-02-25T15:19:03.220Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","source_id_and_acronym":"NCT04805307 - KYM901","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonesitatug vedotin (AZD0901)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 04/05/2024","study_completion_date":" 04/05/2024","last_update_posted":"2025-02-12"},{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"91cef775-8b83-47e1-b58a-9bb196c93393","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770439","created_at":"2025-02-26T07:01:17.629Z","updated_at":"2025-02-26T07:01:17.629Z","phase":"Phase 2","brief_title":"IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06770439","lead_sponsor":"Zhejiang University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-13"},{"id":"d1fb7474-3dd7-44b8-b923-5fc52d65fdb6","acronym":"CLARITY-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06219941","created_at":"2024-01-23T20:21:10.317Z","updated_at":"2024-07-02T16:34:26.279Z","phase":"Phase 2","brief_title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","source_id_and_acronym":"NCT06219941 - CLARITY-PanTumor01","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 01/19/2027","study_completion_date":" 01/19/2027","last_update_posted":"2024-06-13"},{"id":"3a5fd4f8-44a2-4aeb-8b07-da3801ece8f2","acronym":"CLAUDIO-01","url":"https://clinicaltrials.gov/study/NCT05525286","created_at":"2023-11-28T16:15:12.175Z","updated_at":"2024-07-02T16:35:00.868Z","phase":"Phase 1/2","brief_title":"Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05525286 - CLAUDIO-01","lead_sponsor":"SOTIO Biotech a.s.","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOT102"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-27"},{"id":"56340f92-11bf-404d-bdf4-c92c67bb6993","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001516","created_at":"2021-08-12T14:54:30.593Z","updated_at":"2024-07-02T16:35:09.043Z","phase":"Phase 1","brief_title":"Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05001516","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MSI • CLDN18","pipe":" | ","alterations":" MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive","tags":["MSI • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/29/2021","start_date":" 12/29/2021","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-04-17"},{"id":"85e7121a-617b-4471-a40e-31d0ee93b7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT05161390","created_at":"2021-12-17T17:31:06.701Z","updated_at":"2024-07-02T16:35:09.258Z","phase":"Phase 1/2","brief_title":"Study of LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05161390","lead_sponsor":"LaNova Medicines Zhejiang Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 11/26/2021","start_date":" 11/26/2021","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 06/08/2025","study_completion_date":" 06/08/2025","last_update_posted":"2024-04-17"},{"id":"2ac2d1d3-f211-480d-b318-f1f6e888d604","acronym":"CLINCH","url":"https://clinicaltrials.gov/study/NCT05718895","created_at":"2023-02-08T17:00:25.766Z","updated_at":"2024-07-02T16:35:10.403Z","phase":"Phase 1","brief_title":"A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05718895 - CLINCH","lead_sponsor":"Antengene Biologics Limited","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-022"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 03/27/2023","start_date":" 03/27/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-10"},{"id":"b6dec22b-d68a-4e20-acd1-3c108bb7759f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06321913","created_at":"2024-03-22T02:47:21.968Z","updated_at":"2024-07-02T16:35:13.935Z","phase":"Phase 2","brief_title":"Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06321913","lead_sponsor":"Harbin Medical University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/15/2024","start_date":" 03/15/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"62c4f641-e07b-4061-a840-4410a2fd80ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05980416","created_at":"2023-08-08T14:08:21.220Z","updated_at":"2024-07-02T16:35:16.049Z","phase":"Phase 1","brief_title":"Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2","source_id_and_acronym":"NCT05980416","lead_sponsor":"Elevation Oncology","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-06"},{"id":"c9408395-7b13-44ae-876f-d2fa76c22593","acronym":"","url":"https://clinicaltrials.gov/study/NCT05205850","created_at":"2022-01-25T15:53:35.224Z","updated_at":"2024-07-02T16:35:18.604Z","phase":"Phase 1/2","brief_title":"A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT05205850","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/03/2022","start_date":" 03/03/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-20"},{"id":"44b09edb-cd29-47be-ab28-ad38f4d77ec1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05367635","created_at":"2022-05-10T20:53:39.752Z","updated_at":"2024-07-02T16:35:31.999Z","phase":"Phase 1","brief_title":"A Study of SKB315 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05367635","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SKB315"],"overall_status":"Recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2023-10-24"},{"id":"96bebf64-22cc-44fe-8eb7-2b3fcb1d55b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05934331","created_at":"2023-07-06T16:10:33.332Z","updated_at":"2024-07-02T16:35:34.327Z","phase":"Phase 2","brief_title":"A LM-302 Combined With Toripalimab Phase II Study","source_id_and_acronym":"NCT05934331","lead_sponsor":"LaNova Medicines Zhejiang Co., Ltd.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-10-06"},{"id":"f8f53ebe-73d9-402d-b333-b23802618040","acronym":"","url":"https://clinicaltrials.gov/study/NCT05043987","created_at":"2021-09-14T16:53:27.314Z","updated_at":"2024-07-02T16:35:37.794Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers","source_id_and_acronym":"NCT05043987","lead_sponsor":"Conjupro Biotherapeutics, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2023-09-07"},{"id":"c9b51e1f-3400-4df6-8856-b08f7ea1cc7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04914117","created_at":"2021-06-04T14:53:32.830Z","updated_at":"2024-07-02T16:35:45.117Z","phase":"Phase 1","brief_title":"A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours","source_id_and_acronym":"NCT04914117","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ciletatug vedotin (RC118)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 03/11/2023","study_completion_date":" 03/11/2023","last_update_posted":"2023-06-22"},{"id":"855ffc53-c4ec-447b-a6df-ba4b262664bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05458219","created_at":"2022-07-14T13:54:21.525Z","updated_at":"2024-07-02T16:36:00.552Z","phase":"Phase 1","brief_title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05458219","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arcotatug tavatecan (TAK-921)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2022-11-11"},{"id":"de3ef43b-b7ce-4ca6-821c-63d13927851a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009966","created_at":"2021-08-18T15:53:40.109Z","updated_at":"2024-07-02T16:36:22.492Z","phase":"Phase 1","brief_title":"Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor","source_id_and_acronym":"NCT05009966","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EO-3021"],"overall_status":"Recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-10-25"}]